BCAB News and Press, BioAtla Inc.

Context announces buyout of CT-202 future milestones and royalties in exchange for a fully paid-up, non-terminable license Phase 1 initiation for CT-202 trial expected in third quarter of 2026 PHILADELPHIA, May 18, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context”...

2026-05-11 18:50:06 ET BioAtla, Inc. (BCAB) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 9.96%. The average open to low on the day of earnings was -7.62%. The average open to close on...

2026-03-31 16:51:07 ET More on BioAtla BioAtla to implement 50-for-1 share consolidation Financial information for BioAtla Read the full article on Seeking Alpha For further details see: BioAtla GAAP EPS of -$0.16, revenue of $2M

2026-03-31 16:12:14 ET More on BioAtla Financial information for BioAtla Read the full article on Seeking Alpha For further details see: BioAtla to implement 50-for-1 share consolidation

SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ: BCAB or the “Company”), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that ...

Initiated a formal process to monetize assets  Implemented a restructuring plan to significantly reduce operating expenses and extend runway SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the develop...

2026-03-25 18:32:53 ET BioAtla, Inc. (BCAB) - Following Earnings Price Analysis was done using last 12 quarters historical earnings. Opening Gap Moves The historical opening gap move in BCAB stock price following earnings has averaged ±4.50% , with a median of 2.58%. The si...

SAN DIEGO, March 02, 2026 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ: BCAB or the “Company”), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, announced that the Bo...

A look at the top 10 most actives in the United States Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 6.1% to $1.85 on volume of 586,924,470 shares ProShares UltraShort Silver -2x Shares (ZSL) rose 8.5% to $2.56 on volume of 456,074,943 shares iShares Silver Trust (SLV) fell 4.0% t...

A look at the top 10 most actives in the United States China SXT Pharmaceuticals Inc. (SXTC) rose 33.9% to $0.0415 on volume of 661,694,529 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 6.0% to $1.8515 on volume of 515,170,719 shares ProShares UltraShort Silver -2x Shares (...